Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2003

01-09-2003 | Article

Clinical significance of sentinel lymph node involvement in malignant melanoma

Authors: Gabriella Liszkay, Gábor Péley, István Sinkovics, Ilona Péter, Zsolt Orosz, Zsuzsa Fejôs, Béla Horváth, István Köves, Katalin Gilde, Miklós Kásler

Published in: Pathology & Oncology Research | Issue 3/2003

Login to get access
Metadata
Title
Clinical significance of sentinel lymph node involvement in malignant melanoma
Authors
Gabriella Liszkay
Gábor Péley
István Sinkovics
Ilona Péter
Zsolt Orosz
Zsuzsa Fejôs
Béla Horváth
István Köves
Katalin Gilde
Miklós Kásler
Publication date
01-09-2003
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2003
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/BF03033735

Other articles of this Issue 3/2003

Pathology & Oncology Research 3/2003 Go to the issue

Case Report

Renal medullary carcinoma in a six-year-old boy with sickle cell trait

Case Report

Endobronchial large cell neuroendocrine carcinoma

Review

Brain-metastatic melanoma: a neurotrophic perspective

Case Report

Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1

Article

Adjuvant therapy of breast cancer with docetaxel-containing combination (TAC) — A Hungarian experience in the BCIRG 001 trial

Article

Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits